Back to basics: luring industry back into neuroscience

  title={Back to basics: luring industry back into neuroscience},
  author={Steven E Hyman},
  journal={Nature Neuroscience},
or to serve as reliable predictors of treatment efficacy in humans. Members of the investment community and industry leaders noted that capital can flow anywhere and, if invested in therapeutics, will follow the best scientific leads. Knowledge of disease mechanism was asserted as the most important factor in decisions to invest in a particular human condition, because such knowledge provides the best line of sight from drug discovery to clinical trials design to regulatory approval. Absent an… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 56 times over the past 90 days. VIEW TWEETS